































































































































































































































































































































































































































































































































































































































of oxygen concentration in inspired gas on
concentrations of theopylline in control
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Table 2 Slopeofthe terminal log-linear portion of
theophylllne and ant土pyrine plasma concentration
profiles, plasma proteinbindln90f the drugs. and
















a)Four repetitions forthedeterm土natlon of plasma
unbound fraction (fu)and serum proteinconcentrat土on･
Results are means ±S.E. Signlf土cantly different
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Table 3 Description of patient data used in the




Number of patients with





               5
 8.7 ± 4.7 (O.25-18.3)
26.0 ± 12.8 (4.7-63.0)
Total number of rneasurements
  Number of patients with 1 measurement
  Number of patients with 2 measurements
  Number of patients with 3 measurernents
  Number of patients with 4 rneasurements







Sampling time after start
   of infusion (days)
Arninophylline infusion rate
   (mg/hr/kg)
Theophylline concentration
   in the serurn (pg/ml)
3.1 ± 3.1 (O.3- 20)
1.035 ± O.174 (O.625-i.70)
13.9 ± 4.8 (5.2-29.1)




    12 (11 Patients)
66.6 ± 13.9 (52.7-96.0)
37.8 ± 8.1 (27.3-50.0)
7.415 ± O.061 (7.294-7.470)
Number of clinical analyses







































































































































Table4 Hypothesistesting for f土Ⅹedeffectson
theophyll土ne totalbodyclearance

















































Table 5 Flnalestimateofpopulation pharmacokinetic
parameters of theophylline during COnStant-rate






Decreasing factor 土nCLassociatedwith 0.357
hepat土cdysfunct土onb) (0.559-0.155)






















































































































Total number of patients  Disease typea)
    Chronic asthma
    Chronic pulrnonary ernphysema
    Diffuse panbronchiolitis
    Chronic bronchitis
    Other
,Number of maies
Number of patients with hepatic




















 59.0 ± 11
 49.3 ± 11
158.3 ± 10
 71.4 ± 11
 42.5 ± 6
7.402 ± O
 41.6 ± 4






















Co ( yg/rn1 )
     276
    200
 9.21 ± 3.
O.517 ± O.
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Tabie 8 Final estimates for population pharmacokinetic
parameters of theophylline in patients with stable
chronic airway obstruction


















   38.5
    12.5









a) upper and lower limits of 95g confidence intervals
of estimates are given in parentheses.
b) cL=exp(pl+P3.HF+Ps.PaC02) and Vd=exp(P2+P4.PaC02),
where HF is a categorical variable with a value of
unity if a patient is complicated by hepatic
dysfunction otherwise zero, and PaC02 is the arterial
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Fig.18 Serum concentration versus time profiles for
theophylline ln patients with chronic airway
obstruction duringandafteratestdose.Thedrugwas
administered asan intravenous lnfus土on startlng■at
time zero′and its durationvaried from 0.16to 2.58
hr′ depend土ng on the pat土ent's condlt土on. The
























































Fig.19 でyplCal example ofthe one-point Bayeslan
method. The closed circle (●) represents a serum
concentration used ln theBayes土anmethod and open
clrcles (○) representother serum concentrationswhich
were notused in thecalculation. The solid lines
represent the calculated serum concentration-time
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F19.22 Serum concentrations of theophylline ln a
pediatrlcpatientwith asthma
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